Morning Buzz: Clean Diesel (CDTI), AVEO Pharmaceuticals (AVEO), Youku Tudou (YOKU), Regulus Therapeutics (RGLS)

Shares of Clean Diesel Technologies Inc. (CDTI) are higher by nearly 20% to $2.45 in pre-market trading on Tuesday after the company reported compelling vehicle test results for Spinel(TM) technology, its proprietary clean emissions exhaust technology that is expected to dramatically reduce the cost for auto manufacturers to attain increasingly stringent clean air standards.

“These encouraging initial results from rigorous FTP testing demonstrate the significant potential of our Spinel technology,” stated Chris Harris, CDTi’s President and CEO. “These technologies could enable the light and heavy duty vehicle industries to reduce the billions of dollars currently spent on PGMs, as well as address the increasing risks of supply constraints and price volatility surrounding strategic materials like PGMs and rare earths.”

Shares of AVEO Pharmaceuticals (AVEO) were up more than 13% to $2.58 in early trade following positive coverage from Cigna (CI) for VeriStrat test.

Cigna Corporation is one of the largest commercial health plans in the United States with a current membership of 13.3 million people in the US, and 80 million global customer relationships.

Shares of Youku Tudou Inc. (YOKU) spiked higher Tuesday morning after the company announced a partnership with Disney (DIS) for its Marvel marketing platform in China.

YOKU shares recently gained $3.29 to $30.93. In the past 52 weeks, shares of Internet television company in the People’s Republic of China have traded between a low of $11.85 and a high of $31.40. Shares are up 41.74% year-over-year and 55.19% year-to-date.

Regulus Therapeutics (RGLS) shares plunged 13.13% to $11.96 after the company announced that Kleanthis G. Xanthopoulos has resigned as President and Chief Executive Officer and as a member of Regulus’ Board of Directors, effective today. Paul Grint, M.D., who previously served as Chief Medical Officer of Regulus, has been appointed as President and CEO and as a member of Regulus’ Board of Directors effective today.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.